BUZZ-Elevai Labs falls after announcing 1-for-200 stock split

Reuters11-25

** Shares of drug developer Elevai Labs decline 14% to 2 cents before the bell

** Late on Friday, ELAB said it will implement a 1-for-200 reverse stock split

** ELAB says stock split will be effective at midnight on Nov. 27 and is intended to bring the company into compliance with Nasdaq's minimum bid price listing rule

** Separately, co also withdraws offer to exchange 15 mln common shares with Series B preferred stock due to logistical issues

** Says will assess whether to commence a new exchange offer

** As of last close, ELAB stock had nearly halved in value so far this year

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment